Quest Diagnostics Introduces Dako's PD-L1 Companion Diagnostic for KEYTRUDA®
KEYTRUDA is Merck's anti-PD-1 therapy for metastatic non-small cell lung cancer whose tumors express PD-L1 with disease progression on or after platinum-containing chemotherapy